Andraka's winning project consisted of a sensor, similar to diabetic test strips, for early-stage pancreatic cancer screening. The sensor, consisting offilter paper coated with single-walled carbon nanotubes and antibodies against human mesothelin, was said to measure the level of mesothelin to test for the presence of cancer in a patient. The project claimed that tests on human blood serum showed a dose-dependent response, and that his method was 168 times faster, times as expensive, and 400 times more sensitive than ELISA, 25% to 50% more accurate than the CA19-9 test, and over 90 percent accurate in detecting the presence of mesothelin. However, several years of trials would be needed to determine whether the new device would be sensitive and specific enough as a screening test for pancreatic cancer. on open access. Andraka has spoken about the inspiration for his work—including the death of a family friend—in forums including TEDxNijmegen in 2013. He conducted his work under the supervision of Anirban Maitra, Professor of Pathology, Oncology, and Chemical and Biomolecular Engineering at Johns Hopkins School of Medicine. Andraka has applied for a provisional patent for his method of sensing pancreatic cancer and as of 2012 was communicating with companies about developing an over-the-counter test. In October 2013, Andraka appeared as a guest on The Colbert Report to talk about his work.
Criticism
A 2011 article published by Sharon et al. refutes many of Andraka's claims about specificity of using mesothelin as a biomarker for pancreatic cancer. Specifically, the group showed that mesothelin serum levels in healthy donors were not statistically different from serum levels in pancreatic cancer patients. Dr. Ira Pastan, who discovered mesothelin, said that Andraka's method "makes no scientific sense. I don't know anybody in the scientific community who believes his findings." George M. Church, professor of genetics at Harvard University, also raised concerns about the cost, speed, and sensitivity claims. The novelty of Andraka's work has also been questioned. In 2005, seven years before Andraka won the Intel ISEF, a group of researchers at Jefferson Medical College and the University of Delaware reported a carbon-nanotube based sensor for use in breast cancer diagnostics that uses a methodology nearly identical to Andraka's purportedly novel methodology. In addition, a carbon-nanotube based sensor similar to Andraka's was reported in 2009 by Wang et al., a group of researchers at Jiangnan University and University of Michigan, and a carbon-nanotube based sensor for applications in cancer diagnosis was reported in a 2008 paper by Shao et al. that used a methodology similar to Andraka's. In 2012, Andraka filed a "World Patent" under the Patent Cooperation Treaty, which resulted in a preliminary search to determine patentability. The examination found "a lack of inventive step" and prior art in US Patents and . No subsequent patent has been filed in any of the patent offices under the PCT and a "Code 122" was issued on June 3, 2015. While being an advocate for open access, he was criticized for not publishing his discovery openly for anyone to use and build upon, and then trying to file a patent for it.
Personal life
Jack Andraka was born in Crownsville, Maryland and is of Polish ancestry. Andraka enrolled as a freshman at Stanford University for the 2015–2016 academic year. Andraka has been openly gay since he was 13. When asked to be interviewed about his sexual orientation, Andraka responded, "That sounds awesome! I’m openly gay and one of my biggest hopes is that I can help inspire other LGBT youth to get involved in STEM. I didn't have many role models besides Alan Turing."
